CoChat

Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial

Open access
Verguet, Stéphane, Kim, Jane J., Jamison, Dean T. · 2016 · PharmacoEconomics

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Abstract

Health policy instruments such as the public financing of health technologies (e.g., new drugs, vaccines) entail consequences in multiple domains. Fundamentally, public health policies aim at increasing the uptake of effective and efficient interventions and at subsequently leading to better health benefits (e.g., premature mortality and morbidity averted). In addition, public health policies can provide non-health benefits in addition to the sole well-being of populations and beyond the health sector. For instance, public policies such as social and health insurance programs can prevent illness-related impoverishment and procure financial risk protection. Furthermore, public policies can improve the distribution of health in the population and promote the equalization of health among individuals. Extended cost-effectiveness analysis was developed to address health policy assessment, specifically to evaluate the health and financial consequences of public policies in four domains: (1) the health gains; (2) the financial risk protection benefits; (3) the total costs to the policy makers; and (4) the distributional benefits. Here, we present a tutorial that describes both the intent of extended cost-effectiveness analysis and its keys to allow easy implementation for health policy assessment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40273-016-0414-z

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Conceptual structure of the extended cost-effectiveness analysis methodology where policy impact is estimated in four domains across distinct wealth strata of the country population: (1) health gains; (2) private expenditures averted; (3) prevention of illness-related impoverishment or financial risk protection provided; and (4) cost to the implementer
Fig. 1 Conceptual structure of the extended cost-effectiveness analysis methodology where policy impact is estimated in four domains across distinct wealth strata of the country population: (1) health gains; (2) private expenditures averted; (3) prevention of illness-related impoverishment or financial risk protection provided; and (4) cost to the implementerCC BY · PubMed Central
Fig. 2 Estimated distribution across income quintiles in country ‘Land’ of: (a) deaths attributable to diseases D1 and D2 and (b) private expenditures (e.g. out-of-pocket direct medical costs) attributable to the treatment of diseases D1 and D2
Fig. 2 Estimated distribution across income quintiles in country ‘Land’ of: (a) deaths attributable to diseases D1 and D2 and (b) private expenditures (e.g. out-of-pocket direct medical costs) attributable to the treatment of diseases D1 and D2CC BY · PubMed Central
Fig. 3 Estimated distribution across income quintiles in Ethiopia of: (a) rotavirus-related deaths averted; (b) rotavirus-related private expenditures crowded out; and (c) financial risk protection afforded (measured by a money-metric value of insurance), with universal public finance of rotavirus immunization. Source: based on estimates from [48]
Fig. 3 Estimated distribution across income quintiles in Ethiopia of: (a) rotavirus-related deaths averted; (b) rotavirus-related private expenditures crowded out; and (c) financial risk protection afforded (measured by a money-metric value of insurance), with universal public finance of rotavirus immunization. Source: based on estimates from [48]CC BY · PubMed Central
Fig. 4 Deaths averted and financial risk protection (measured by a money-metric value of insurance) afforded with universal public finance for rotavirus immunization, per $1 million spent, India (vaccine price of $5.0) and Ethiopia (vaccine price of $0.40). Income quintiles: I = poorest, II = poorer, III = middle, IV = richer, V = richest. Source: based on estimates from [48]
Fig. 4 Deaths averted and financial risk protection (measured by a money-metric value of insurance) afforded with universal public finance for rotavirus immunization, per $1 million spent, India (vaccine price of $5.0) and Ethiopia (vaccine price of $0.40). Income quintiles: I = poorest, II = poorer, III = middle, IV = richer, V = richest. Source: based on estimates from [48]CC BY · PubMed Central
Fig. 5 Financial risk protection afforded (poverty cases averted) vs. health gains (deaths averted), per $100,000 spent (in 2011 US$), for each of nine interventions provided through universal public finance in Ethiopia. Source: adapted from [28]
Fig. 5 Financial risk protection afforded (poverty cases averted) vs. health gains (deaths averted), per $100,000 spent (in 2011 US$), for each of nine interventions provided through universal public finance in Ethiopia. Source: adapted from [28]CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 60 references

Cited by

See all 278

Metadata

Authors
Verguet, S., Kim, J. J., & Jamison, D. T.
Affiliations
  • Harvard University (US)
  • University of California, San Francisco (US)
Corresponding author
Verguet, Stéphane
Venue
PharmacoEconomics
Published
2016-07-04
Volume
34
Issue
9
Pages
913-923
ISSN
  • 1170-7690 (ISSN-L)
  • 1179-2027
OpenAlex
W2470373670
Cited by
251
References
59
Citations by year
2026: 22 · 2025: 23 · 2024: 44 · 2023: 38 · 2022: 20 · 2021: 24 · 2020: 34 · 2019: 10 · 2018: 16 · 2017: 18 · 2016: 2
FWCI
29.79
Type
journal article
Language
en
Open access
Locations
  • PharmacoEconomics (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Global Health Care Issues
Keywords
health policy evaluation, financial protection, health disparities, distributional effects, policy costs
MeSH terms
Cost-Benefit Analysis, Financing, Government, Health Policy, Humans, Insurance, Health, Public Health, Public Policy, Biomedical Technology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial. https://app.cochat.ai/papers/10.1007/s40273-016-0414-z
The paper
Verguet, S., Kim, J. J., & Jamison, D. T. (2016). Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial. PharmacoEconomics. https://doi.org/10.1007/s40273-016-0414-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.